Key result
The PNPLA3 rs738409 polymorphism was significantly associated with an increased risk of nonalcoholic fatty liver disease (OR 3.41) and nonalcoholic steatohepatitis (OR 4.44).
Why the study?
Does the PNPLA3 rs738409 polymorphism increase the risk of NAFLD and NASH in the general population?
Meta-Analysis (n=16,437)
Does the PNPLA3 rs738409 polymorphism increase the risk of NAFLD and NASH in the general population?
Odds Ratio: 3.41 (95% CI 2.57–4.52)
p-value: p=<0.00001
The PNPLA3 rs738409 polymorphism is a significant genetic risk factor for the development of NAFLD and NASH across multiple ethnicities.
Supports genetic risk stratification in NAFLD; confirms PNPLA3 as major susceptibility factor across ethnicities.
We conducted a meta-analysis to assess the association between patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) and its subtypes simple steatosis(SS) and nonalcoholic steatohepatitis (NASH). The study-specific odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed-effects or random-effects models, with assessment for heterogeneity and publication bias. Twenty-three case-control studies involving 6071 NAFLD patients and 10366 controls were identified. The combined results showed a significant association between NAFLD risk and the rs738409 polymorphism in all genetic models (additive model: OR = 3.41, 95% CI = 2.57-4.52; P < 0.00001). In addition, evidence indicated that the rs738409 polymorphism was significantly associated with NASH in all genetic models (additive model: OR = 4.44, 95% CI = 3.39-5.82; P < 0.00001). The subgroup and sensitivity analyses showed that these changes were not influenced by the ethnicities and ages of subjects or by the source of controls. The rs738409 polymorphism was only significantly associated with risk of simple steatosis in the allele contrast and had no effect in the other genetic models. These findings suggest that the rs738409 polymorphism in PNPLA3 gene confers high cross-ethnicity risk for NAFLD and NASH development.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2015) conducted a meta-analysis in Nonalcoholic fatty liver disease (NAFLD) (n=16,437). PNPLA3 rs738409 polymorphism vs. Controls without the polymorphism was evaluated on Nonalcoholic fatty liver disease (NAFLD) risk (additive model) (OR 3.41, 95% CI 2.57-4.52, p=<0.00001). The PNPLA3 rs738409 polymorphism was significantly associated with an increased risk of nonalcoholic fatty liver disease (OR 3.41) and nonalcoholic steatohepatitis (OR 4.44).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: